Khuc Thao A, Pequeno Gregery, Betancourt-Garcia Monica, Casciato Adrienne M, Gomez-Martinez Marissa, Arroyo Carlos D, Pope Bill D, Narmala Shravan, Rao Sohail
Medicine, Doctor's Hospital Renaissance (DHR) Health Institute for Research and Development, Edinburg, USA.
Center of Excellence for Trauma Research in the Border Region, Doctor's Hospital Renaissance (DHR) Health Institute for Research and Development, Edinburg, USA.
Cureus. 2023 Jul 11;15(7):e41696. doi: 10.7759/cureus.41696. eCollection 2023 Jul.
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the Centers for Disease Control and Prevention (CDC) authorized the third dose of the Pfizer-BioNTech (BNT162b2) vaccine with the rationale for prolonged elevation of anti-SARS-CoV-2 antibody titers and protection against the SARS-CoV-2 virus. To better understand how administration of the third dose of the Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine affects the incidence and severity of SARS-CoV-2 infections, we administered the third dose of the Pfizer-BioNTech (BNT162b2) to 189 participants. Blood samples were collected from participants during each of their scheduled visits (baseline, week two, week 12, and week 24) and tested for semi-quantitative anti-SARS-CoV-2 immunoglobulin G (IgG) titers. Our results showed that administration of the third dose of the Pfizer-BioNTech (BNT162b2) vaccine elicited elevated anti-SARS-CoV-2 IgG antibodies for the 24-week duration of the study. IgG antibody titers were greatest in week two, and progressively decreased by week 12 and week 24, with statistically significant differences between the IgG antibody titers for each collection date.
随着严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的出现，美国疾病控制与预防中心（CDC）批准了辉瑞-生物科技公司（BNT162b2）疫苗的第三剂接种，理由是抗SARS-CoV-2抗体滴度可长期升高并预防SARS-CoV-2病毒。为了更好地了解辉瑞/生物科技公司2019冠状病毒病（COVID-19）疫苗第三剂的接种如何影响SARS-CoV-2感染的发生率和严重程度，我们对189名参与者接种了辉瑞-生物科技公司（BNT162b2）的第三剂疫苗。在参与者的每次预定访视（基线、第2周、第12周和第24周）期间采集血样，并检测半定量抗SARS-CoV-2免疫球蛋白G（IgG）滴度。我们的结果表明，在研究的24周期间，辉瑞-生物科技公司（BNT162b2）疫苗第三剂的接种引发了抗SARS-CoV-2 IgG抗体的升高。IgG抗体滴度在第2周时最高，并在第12周和第24周逐渐下降，每个采集日期的IgG抗体滴度之间存在统计学显著差异。
